Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas

Experimental Dermatology

Volumn 17, Issue 11, 2008, Pages 908-915

  Stoebner, Pierre E ^a,b   Le Gallic, Lionel ^c   Berthe, Marie L ^d   Boulle, Nathalie ^d   Lallemant, Benjamin ^b   Marque, Myriam ^b   Gaspard, Catherine ^e   Delfour, Christophe ^b   Lavabre Bertrand, Thierry ^c   Martinez, Jean ^a   Meunier, Laurent ^a,b  

^a CNRS   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

^c Facultéde Médecine ^*  (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

^e Pathology Center of Montpellier   (France)

Author keywords

Angiogenesis; Basal cell carcinoma; Immunohistochemistry; Platelet derived endothelial cell growth factor; Thymidine phosphorylase

Indexed keywords

FORMALDEHYDE; MESSENGER RNA; MONOCLONAL ANTIBODY; PARAFFIN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THYMIDINE PHOSPHORYLASE; TUMOR MARKER;

ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MELANOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; SYRINGOMA; TRANSCRIPTION REGULATION; TRICHOBLASTOMA; TUMOR CELL; TUMOR DIFFERENTIATION;

CARCINOMA, BASAL CELL; CARCINOMA, BASOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KERATOSIS, ACTINIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; THYMIDINE PHOSPHORYLASE;

EID: 54049151618     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00718.x     Document Type: Article

References (46)

1. Friedkin M, Roberts D. The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J Biol Chem 1954: 207: 245-256.
2. Miyazono K, Okabe T, Urabe A et al. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 1987: 262: 4098-4103.
3. Ishikawa F, Miyazono K, Hellman U et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989: 338: 557-562.
4. Lee S S, Giovanella B C, Stehlin J S Jr. Effect of excess thymidine on the growth of human melanoma cells transplanted in thymus deficient nude mice. Cancer Lett 1977: 3: 209-214.
5. Schwartz P M, Reuveni H, Milstone L M. Local and systemic implications of thymidine catabolism by human keratinocytes. Ann N Y Acad Sci 1988: 548: 115-124.
6. Moghaddam A, Zhang H T, Fan T P et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995: 92: 998-1002.
7. Akiyama S, Furukawa T, Sumizawa T et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci 2004: 95: 851-857.
8. Toi M, Atiqur Rahman M, Bando H et al. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005: 6: 158-166.
9. Gotanda T, Haraguchi M, Tachiwada T et al. Molecular basis for the involvement of thymidine phosphorylase in cancer invasion. Int J Mol Med 2006: 17: 1085-1091.
10. Jeung H C, Che X F, Haraguchi M et al. Protection against DNA damage-induced apoptosis by the angiogenic factor thymidine phosphorylase. FEBS Lett 2006: 580: 1294-1302.
11. Liekens S, Bronckaers A, Perez-Perez M J et al. Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem Pharmacol 2007 May 16. Biochem Pharmacol 2007: 74: 1555-1567.
12. Fukushima M, Okabe H, Takechi T et al. Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity. Cancer Lett 2002: 187: 103-110.
13. Schwartz P M, Milstone L M. Thymidine phosphorylase in human epidermal keratinocytes. Biochem Pharmacol 1988: 37: 353-355.
14. Asgari M M, Haggerty J G, McNiff J M et al. Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors. J Cutan Pathol 1999: 26: 287-294.
15. Hammerberg C, Fisher G J, Voorhees J J et al. Elevated thymidine phosphorylase activity in psoriatic lesions accounts for the apparent presence of an epidermal "growth inhibitor," but is not in itself growth inhibitory. J Invest Dermatol 1991: 97: 286-290.
16. Creamer D, Jaggar R, Allen M et al. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 1997: 137: 851-855.
17. Kore-eda S, Horiguchi Y, Ueda M et al. Basal cell carcinoma cells resemble follicular matrix cells rather than follicular bulge cells: immunohistochemical and ultrastructural comparative studies. Am J Dermatopathol 1998: 20: 362-369.
18. Stoebner P E, Lavabre-Bertrand T, Henry L et al. High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol 2005: 152: 948-953.
19. Delfour C, Roger P, Bret C et al. RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells. J Mol Diagn 2006: 8: 157-169.
20. Ijuin T, Nibu K, Doi K et al. Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer. Acta Otolaryngol 2007: 127: 305-311.
21. Leibovitch I, Huilgol S C, Selva D et al. Basosquamous carcinoma: treatment with Mohs micrographic surgery. Cancer 2005: 104: 170-175.
22. Collie-Duguid E S, Johnston S J, Boyce L et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. Int J Cancer 2001: 94: 297-301.
23. Fujiwaki R, Hata K, Nakayama K et al. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. J Clin Oncol 2000: 18: 3946-3951.
24. Hotta T, Taniguchi K, Kobayashi Y et al. Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers. Oncol Rep 2004: 11: 1045-1051.
25. Tang W, Wang X, Utsunomiya H et al. Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: Histological features and microvessel density. Cancer Lett 2000: 148: 153-159.
26. Kuramochi H, Hayashi K, Uchida K et al. 5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. Int J Cancer 2006: 119: 522-526.
27. Giatromanolaki A, Koukourakis M I, Comley M et al. Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J Pathol 1997: 181: 196-199.
28. Okada K, Yokoyama K, Okihara K et al. Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate. Urology 2001: 57: 376-381.
29. Oh C K, Kwon Y W, Kim Y S et al. Expression of basic fibroblast growth factor, vascular endothelial growth factor, and thrombospondin-1 related to microvessel density in nonaggressive and aggressive basal cell carcinomas. J Dermatol 2003: 30: 306-313.
30. Bowden J, Brennan P A, Umar T et al. Expression of vascular endothelial growth factor in basal cell carcinoma and cutaneous squamous cell carcinoma of the head and neck. J Cutan Pathol 2002: 29: 585-589.
31. Loggini B, Boldrini L, Gisfredi S et al. CD34 microvessel density and VEGF expression in basal and squamous cell carcinoma. Pathol Res Pract 2003: 199: 705-712.
32. O'Grady A, O'Kelly P, Murphy G M et.al. COX-2 expression correlates with microvessel density in non-melanoma skin cancer from renal transplant recipients and immunocompetent individuals. Hum Pathol 2004: 35: 1549-1555.
33. Tjiu J W, Liao Y H, Lin S J et al. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol 2006: 126: 1143-1151.
34. Kikuno N, Yoshino T, Urakami S et al. The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer. Anticancer Res 2003: 23: 1305-1312.
35. Miyake K, Imura S, Yoshizumi T et al. Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer. Int J Clin Oncol 2007: 12: 111-119.
36. Weninger W, Rendl M, Pammer J et al. Differences in tumor microvessel density between squamous cell carcinomas and basal cell carcinomas may relate to their different biologic behavior. J Cutan Pathol 1997: 24: 364-369.
37. Chin C W, Foss A J, Stevens A et al. Differences in the vascular patterns of basal and squamous cell skin carcinomas explain their differences in clinical behaviour. J Pathol 2003: 200: 308-313.
38. Saldanha G, Fletcher A, Slater D N. Basal cell carcinoma: A dermatopathological and molecular biological update. Br J Dermatol 2003: 148: 195-202.
39. Athar M, Tang X, Lee J L et al. Hedgehog signalling in skin development and cancer. Exp Dermatol 2006: 15: 667-677.
40. Van Doorn R, Gruis N A, Willemze R et al. Aberrant DNA methylation in cutaneous malignancies. Semin Oncol 2005: 32: 479-487.
41. Goldberg M, Rummelt C, Laerm A et al. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas. Br J Dermatol 2006: 155: 1154-1158.
42. Guarcello V, Blanquicett C, Naguib F N et al. Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity. Cancer Chemother Pharmacol 2007 Sep 1.
43. Schwartz P M, Barnett S K, Reuveni H. Thymidine salvage changes with differentiation in human keratinocytes in vitro. J Invest Dermatol 1991: 97: 1057-1060.
44. Kaddu S, Kerl H. Benign epithelial tumors. In: Freedberg I M, Eisen A Z, Wolff K, Austen K F, Goldsmith L A, Katz S I, eds. Fitzpatrick's Dermatology in General Medicine, 6th edn. New York, NY: McGraw-Hill, 2003: 785-808.
45. Eda H, Fujimoto K, Watanabe S et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993: 32: 333-338.
46. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: Efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 2007: 33: 433-439.